Literature DB >> 10231726

Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types.

D K Lahiri1.   

Abstract

Melatonin is released in mammals during the dark phase of the circadian cycle, and its production declines with age in animals and humans. Since supplemental administration of melatonin may be beneficial in delaying age-related degenerative conditions, it is necessary to study its effect on neuronal differentiation and the processing of key neuronal proteins, such as beta-amyloid precursor protein (beta APP) and synaptophysin. One of the important pathological hallmarks of Alzheimer's disease (AD) is the cerebrovascular deposition of amyloid plaques. The amyloid in senile plaques is mainly composed of the amyloid beta-peptide (A beta) of 39-43 amino acids derived from a larger beta APP. The proteolytic cleavage by 'alpha-secretase' generate soluble derivatives of beta APP (sAPP), lacking the cytoplasmic tail, transmembrane domain, and a small portion of the extracellular domain. Here levels of sAPP and beta APP were analyzed in cell lines of different origins by Western immunoblot of samples from conditioned media and cell lysates, respectively. Normal levels of secretion of sAPP into conditioned media were severely inhibited by treating different cell lines with a high dose of melatonin. In PC12 cells, levels of the fully matured beta APP forms of the post-Golgi compartment were more drastically decreased than the unglycosylated beta APP of the endoplasmic-reticulum (ER) forms. In other cell types, the unglycosylated ER-bound beta APP derivatives are predominant forms that were marginally affected by melatonin treatment. When the treatment of cells with melatonin was withdrawn, the normal level of secretion of sAPP was restored. Melatonin reduces the secretion of soluble A beta. Melatonin also inhibits the secretion of synaptophysin in PC12 cells. Taken together, these data suggest that melatonin probably affects the secretion of sAPP in the conditioned medium by interfering with its full maturation, and melatonin also affects the presysnaptic terminal marker.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231726     DOI: 10.1111/j.1600-079x.1999.tb00575.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  21 in total

1.  Inhibition of melatonin biosynthesis induces neurofilament hyperphosphorylation with activation of cyclin-dependent kinase 5.

Authors:  Shaohui Wang; Lingqiang Zhu; Hairong Shi; Hongyun Zheng; Qing Tian; Qun Wang; Rong Liu; Jian-Zhi Wang
Journal:  Neurochem Res       Date:  2007-03-31       Impact factor: 3.996

2.  Influence of the Circadian System on Disease Severity.

Authors:  Mikhail Litinski; Frank Ajl Scheer; Steven A Shea
Journal:  Sleep Med Clin       Date:  2009-06-01

3.  Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease.

Authors:  Hongwen He; Weiguo Dong; Fang Huang
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

Review 4.  Snapshot: implications for melatonin in endoplasmic reticulum homeostasis.

Authors:  Wei Hu; Zhiqiang Ma; Shouyin Di; Shuai Jiang; Yue Li; Chongxi Fan; Yang Yang; Dongjin Wang
Journal:  Br J Pharmacol       Date:  2016-11-16       Impact factor: 8.739

5.  A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Carlos Spuch; Desiree Antequera; M Isabel Fernandez-Bachiller; M Isabel Rodríguez-Franco; Eva Carro
Journal:  Neurotox Res       Date:  2009-09-23       Impact factor: 3.911

6.  Impact of Melatonin on Full-Term Fetal Brain Development and Transforming Growth Factor-β Level in a Rat Model of Preeclampsia.

Authors:  Nanees Fouad El-Malkey; Mohammed Aref; Hassan Emam; Sama Salah Khalil
Journal:  Reprod Sci       Date:  2021-02-16       Impact factor: 3.060

7.  Anti-inflammatory effect of melatonin on A beta vaccination in mice.

Authors:  E Philip Jesudason; B'Joe Baben; Ben S Ashok; J Gunasingh Masilamoni; R Kirubagaran; W Charles E Jebaraj; R Jayakumar
Journal:  Mol Cell Biochem       Date:  2006-11-29       Impact factor: 3.842

Review 8.  Melatonin in Alzheimer's disease.

Authors:  Li Lin; Qiong-Xia Huang; Shu-Sheng Yang; Jiang Chu; Jian-Zhi Wang; Qing Tian
Journal:  Int J Mol Sci       Date:  2013-07-12       Impact factor: 5.923

Review 9.  Repurposing Licensed Drugs for Use Against Alzheimer's Disease.

Authors:  Leslie C Norins
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 10.  Regulation of Melatonin and Neurotransmission in Alzheimer's Disease.

Authors:  Jaydeep Roy; Ka Chun Tsui; Jonah Ng; Man-Lung Fung; Lee Wei Lim
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.